They want the grace period extended by a further two years, from 2024 to 2026 for the highest risk class products (Class III and implantables), and by four years, from 2024 to 2028, for all other devices.
Currently, the grace period gives eligible manufacturers an additional three years beyond the 26 May 2021 date of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?